2019 Annual Report
Identify drug-candidates, establish initial proof-of-concept, and confirm potential to deliver improved benefits to patients in cancers challenged by unmet medical needs.
Execute important clinical trials to support registrational drug-candidate submissions with FDA, and evaluate the broader potential clinical utility of drug-candidates in new indications and in combination with other oncology drug classes.
Obtain marketing approvals, provide new options to physicians to deliver better clinical outcomes, and improve quality of life for patients.
Each of our four clinical-stage drug candidates target distinct mechanisms critical to overcoming cancer progression and drug resistance:
This past year we’ve remained on course, executing a straightforward, purposeful strategy to advance our pipeline of four clinical-stage oncology candidates and build a strong foundation to deliver value to our stakeholders.Read More >>